Division of Neurosurgery, St. Michael's Hospital, Toronto, Ontario, Canada.
World Neurosurg. 2010 Jun;73(6):646-53. doi: 10.1016/j.wneu.2010.03.032.
Statins have been studied in patients with aneurysmal subarachnoid hemorrhage (SAH) but the history, pharmacology, and studies have not been reviewed recently.
The development of statins as well as their biological effects and pharmacology are reviewed. Recent clinical studies in patients with SAH are summarized.
Statins lower serum cholesterol but they also have antioxidant, anti-inflammatory, vasodilatory, angiogenic, neuroprotective, vasoprotective, and endothelial preserving actions. In patients with SAH, they may decrease the incidence of symptomatic vasospasm, although the effects on overall outcome are less clear. They should be continued in patients who are taking them on admission and perhaps initiated in those who have indications for them. Side effects are rare.
A large randomized, double-blind clinical trial is needed before it can be determined that statins are beneficial for patients with aneurysmal SAH.
他汀类药物已在颅内动脉瘤性蛛网膜下腔出血（SAH）患者中进行了研究，但此类药物的历史、药理学和研究尚未得到最新的综述。
本文综述了他汀类药物的发展以及它们的生物学作用和药理学。总结了最近 SAH 患者的临床研究。
他汀类药物可降低血清胆固醇，但也具有抗氧化、抗炎、血管舒张、血管生成、神经保护、血管保护和内皮保护作用。在 SAH 患者中，它们可能会降低症状性血管痉挛的发生率，尽管它们对整体预后的影响尚不明确。对于入院时正在服用他汀类药物的患者，应继续服用，对于有适应证的患者，或许可以开始服用。副作用罕见。
在确定他汀类药物对颅内动脉瘤性蛛网膜下腔出血患者有益之前，需要进行大型随机、双盲临床试验。
